000963 华东医药
已收盘 06-12 15:00:00
资讯
新帖
简况
华东医药(000963.SZ)：注射用聚己内酯微球面部填充剂医疗器械注册申请获受理
智通财经 · 06-09
华东医药(000963.SZ)：注射用聚己内酯微球面部填充剂医疗器械注册申请获受理
华东医药：公司应收账款随销售收入的增长相应增加这是正常现象
证券之星 · 06-04
华东医药：公司应收账款随销售收入的增长相应增加这是正常现象
华东医药：将于2026年6月ADA大会口头报告HDM1002二期临床研究结果
证券之星 · 06-04
华东医药：将于2026年6月ADA大会口头报告HDM1002二期临床研究结果
华东医药：今年公司肿瘤管线的数据读出将主要集中在今年下半年
证券之星 · 05-27
华东医药：今年公司肿瘤管线的数据读出将主要集中在今年下半年
华东医药：次要终点指标包含LSM相对基线的变化、纤维化生物标志物等
证券之星 · 05-27
华东医药：次要终点指标包含LSM相对基线的变化、纤维化生物标志物等
华东医药：正和相关部门保持沟通
证券之星 · 05-27
华东医药：正和相关部门保持沟通
华东医药：市值管理以夯实基本面为核心
证券之星 · 05-27
华东医药：市值管理以夯实基本面为核心
华东医药：已公布的为新批次集采预填报药品目录
证券之星 · 05-27
华东医药：已公布的为新批次集采预填报药品目录
华东医药：百令胶囊在集采中中标价格调整较小
证券之星 · 05-27
华东医药：百令胶囊在集采中中标价格调整较小
华东医药：自研创新药HDM1002、HDM1005、DR10624三款核心品种已推进至Ⅲ期临床
证券之星 · 05-27
华东医药：自研创新药HDM1002、HDM1005、DR10624三款核心品种已推进至Ⅲ期临床
华东医药(000963.SZ)：赛乐信®和赛捷宁®克罗恩病适应症获批上市
智通财经 · 05-21
华东医药(000963.SZ)：赛乐信®和赛捷宁®克罗恩病适应症获批上市
华东医药（000963）披露将参加深交所2025年度集体业绩说明会，5月14日股价下跌1.41%
证券之星 · 05-14
华东医药（000963）披露将参加深交所2025年度集体业绩说明会，5月14日股价下跌1.41%
华东医药最新公告：全资子公司注射用HDM2017获临床试验批准
证券之星 · 05-13
华东医药最新公告：全资子公司注射用HDM2017获临床试验批准
股市必读：华东医药（000963）5月8日董秘有最新回复
证券之星 · 05-11
股市必读：华东医药（000963）5月8日董秘有最新回复
华东医药：医美业务经营业绩已完整、准确地体现在公司财务报表中
证券之星 · 05-08
华东医药：医美业务经营业绩已完整、准确地体现在公司财务报表中
华东医药：HDM3001克罗恩病适应症预计2026年Q2获批
证券之星 · 05-08
华东医药：HDM3001克罗恩病适应症预计2026年Q2获批
华东医药：HDM1005的MASH适应症已获得中国和美国IND批准
证券之星 · 05-08
华东医药：HDM1005的MASH适应症已获得中国和美国IND批准
华东医药：公司自创新转型以来，持续加大研发投入，目前已逐步进入收获期
证券之星 · 04-29
华东医药：公司自创新转型以来，持续加大研发投入，目前已逐步进入收获期
【机构调研记录】东海基金调研理邦仪器、华东医药等4只个股（附名单）
证券之星 · 04-28
【机构调研记录】东海基金调研理邦仪器、华东医药等4只个股（附名单）
30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧
21世纪经济报道 · 04-27
30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧
公司概况
公司名称：
华东医药股份有限公司
所属行业：
零售业
上市日期：
2000-01-27
主营业务：
华东医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是商业、制造业、医美业务。
发行价格：
5.76
{"stockData":{"symbol":"000963","market":"SZ","secType":"STK","nameCN":"华东医药","latestPrice":29.11,"timestamp":1781247822000,"preClose":29.13,"halted":0,"volume":15457921,"delay":0,"changeRate":-0.0007,"floatShares":1753000000,"shares":1754000000,"eps":1.9968,"marketStatus":"已收盘","change":-0.02,"latestTime":"06-12 15:00:00","open":28.89,"high":29.46,"low":28.45,"amount":449000000,"amplitude":0.0347,"askPrice":29.12,"askSize":48,"bidPrice":29.11,"bidSize":721,"shortable":0,"etf":0,"ttmEps":1.9968,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781487000000},"marketStatusCode":5,"adr":0,"adjPreClose":29.13,"symbolType":"stock","openAndCloseTimeList":[[1781227800000,1781235000000],[1781240400000,1781247600000]],"highLimit":32.04,"lowLimit":26.22,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1753736848,"isCdr":false,"pbRate":1.99,"roa":"--","peRate":14.578325,"roe":"3.97%","epsLYR":1.9484,"committee":0.234043,"marketValue":51051000000,"turnoverRate":0.0088,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-06-15。","floatMarketCap":51030000000},"requestUrl":"/m/hq/s/000963/wiki","defaultTab":"wiki","newsList":[{"id":"2642150468","title":"华东医药(000963.SZ)：注射用聚己内酯微球面部填充剂医疗器械注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2642150468","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642150468?lang=zh_cn&edition=full","pubTime":"2026-06-09 16:15","pubTimestamp":1780992909,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 华东医药 发布公告，2026年6月8日，公司全资子公司欣可丽美学(杭州)供应链管理有限公司收到国家药品监督管理局签发的《受理通知书》，其代理申报的三类医疗器械注射用聚己内酯微球面部填充剂Ellansé伊妍仕S型拓展新适用症的变更注册申请获得受理，本次申请新增适用症：用于额部皮下或骨膜上植入，以改善中至重度额部轮廓缺陷。公司后续将继续全力开展这款产品在中国的注册工作，推动其新适用症早日获批。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","159883","BK0209","BK0175","BK1100","BK0132","000963","BK0187","LU2328871848.SGD","BK0196","BK0188","BK1574","LU1969619763.USD","09996","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640335011","title":"华东医药：公司应收账款随销售收入的增长相应增加这是正常现象","url":"https://stock-news.laohu8.com/highlight/detail?id=2640335011","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640335011?lang=zh_cn&edition=full","pubTime":"2026-06-04 09:06","pubTimestamp":1780535165,"startTime":"0","endTime":"0","summary":"您问题中提及的数字经判断主要涉及公司财务报告中应收账款事项。公司应收账款金额主要和医药商业业务相关，因医药商业销售主要客户为浙江省内各大公立医院，销售回款存在一定账期，这是由医药商业的业务模式决定的，也在财报数据中得到反映。公司应收账款随销售收入的增长相应增加这是正常现象。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400005185.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0187","BK0175","BK0188","BK0209","LU2328871848.SGD","BK0132","BK0196","LU1969619763.USD","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640133361","title":"华东医药：将于2026年6月ADA大会口头报告HDM1002二期临床研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2640133361","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640133361?lang=zh_cn&edition=full","pubTime":"2026-06-04 09:03","pubTimestamp":1780534989,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药(000963)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：1002的降糖二期结束这么久了，数据还不公布吗华东医药回复：您好！公司将于2026年6月举行的美国糖尿病协会（ADA）大会上以口头报告的方式展示HDM1002糖尿病适应症二期临床研究结果。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400005107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963","BK0175","BK0187","BK0132","BK0196","BK0188","LU2328871848.SGD","LU1969619763.USD","BK0209","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638357408","title":"华东医药：今年公司肿瘤管线的数据读出将主要集中在今年下半年","url":"https://stock-news.laohu8.com/highlight/detail?id=2638357408","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638357408?lang=zh_cn&edition=full","pubTime":"2026-05-27 15:06","pubTimestamp":1779865581,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药(000963)05月26日在投资者关系平台上答复投资者关心的问题。投资者提问：ASCO会议，公司连一个像样点的临床/临床前阶段的数据都拿不出来吗，不知道研发费用都花哪儿去了，很难想象公司的肿瘤管线还占了公司所有管线近半数之多，不如把研发费用集中到代谢领域华东医药回复：您好！今年公司肿瘤管线的数据读出将主要集中在今年下半年。感谢您的关注！以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700024516.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0183","BK0188","LU1969619763.USD","LU2328871848.SGD","BK0175","BK0209","000963","BK0132","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638574073","title":"华东医药：次要终点指标包含LSM相对基线的变化、纤维化生物标志物等","url":"https://stock-news.laohu8.com/highlight/detail?id=2638574073","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638574073?lang=zh_cn&edition=full","pubTime":"2026-05-27 15:06","pubTimestamp":1779865580,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药05月26日在投资者关系平台上答复投资者关心的问题。投资者提问：dr10624的mash二期临床设计，终点指标并没有核心指标纤维化逆转数据，请问公司作何考虑。目前正在开展的DR10624用于代谢相关脂肪性肝病的Ⅱ期临床研究，次要终点指标包含LSM相对基线的变化、纤维化生物标志物等，可提示肝纤维化是否得到改善、是否存在逆转趋势。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700024511.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0183","BK0175","BK0187","LU2328871848.SGD","000963","BK0196","BK0132","LU1969619763.USD","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638573550","title":"华东医药：正和相关部门保持沟通","url":"https://stock-news.laohu8.com/highlight/detail?id=2638573550","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638573550?lang=zh_cn&edition=full","pubTime":"2026-05-27 11:34","pubTimestamp":1779852857,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药05月26日在投资者关系平台上答复投资者关心的问题。根据国家组织药品联合采购办公室发布的相关公告，已公布的为新批次集采预填报药品目录，新批次国家药品集中采购品种最终范围、企业投标资质要求等，以后续发布的采购公告为准。公司就子公司纳入此次预填报目录的部分品种正和相关部门保持沟通。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700019750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0175","BK0196","000963","LU1969619763.USD","BK0209","BK0183","LU2328871848.SGD","BK0132","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638735895","title":"华东医药：市值管理以夯实基本面为核心","url":"https://stock-news.laohu8.com/highlight/detail?id=2638735895","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638735895?lang=zh_cn&edition=full","pubTime":"2026-05-27 11:34","pubTimestamp":1779852856,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药05月26日在投资者关系平台上答复投资者关心的问题。市值管理以夯实基本面为核心，同时规范披露、加强资本市场沟通，传递公司价值。创新药海外授权合作是涉及商务、法规、市场及战略匹配的复杂过程。未来如达成明确合作协议，公司将严格按照信息披露规则履行披露义务。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700019747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","000963","BK0209","BK0196","LU1969619763.USD","BK0132","LU2328871848.SGD","BK0188","BK0187","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638573525","title":"华东医药：已公布的为新批次集采预填报药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2638573525","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638573525?lang=zh_cn&edition=full","pubTime":"2026-05-27 11:34","pubTimestamp":1779852853,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药05月26日在投资者关系平台上答复投资者关心的问题。根据国家组织药品联合采购办公室发布的相关公告，已公布的为新批次集采预填报药品目录，新批次国家药品集中采购品种最终范围、企业投标资质要求等，以后续发布的采购公告为准。公司就子公司纳入此次预填报目录的部分品种正和相关部门保持沟通。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700019743.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0175","BK0183","000963","BK0209","BK0188","BK0132","LU2328871848.SGD","LU1969619763.USD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638560573","title":"华东医药：百令胶囊在集采中中标价格调整较小","url":"https://stock-news.laohu8.com/highlight/detail?id=2638560573","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638560573?lang=zh_cn&edition=full","pubTime":"2026-05-27 11:34","pubTimestamp":1779852849,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药05月26日在投资者关系平台上答复投资者关心的问题。以上，辛苦解答华东医药回复：您好！百令胶囊已于2024年底在全国中成药联盟集采续约中成功中选，中标价格调整较小。根据国家组织药品联合采购办公室发布的相关公告，已公布的为新批次集采预填报药品目录，新批次国家药品集中采购品种最终范围、企业投标资质要求等，以后续发布的采购公告为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700019737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0187","000963","BK0175","LU2328871848.SGD","LU1969619763.USD","BK0209","BK0188","BK0132","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638787565","title":"华东医药：自研创新药HDM1002、HDM1005、DR10624三款核心品种已推进至Ⅲ期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2638787565","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638787565?lang=zh_cn&edition=full","pubTime":"2026-05-27 11:33","pubTimestamp":1779852830,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药05月26日在投资者关系平台上答复投资者关心的问题。股票二级市场的波动受宏观经济、行业政策、市场情绪等多重因素影响。自研新药研发周期长、投入门槛高，具备客观行业规律。公司目前自研创新药HDM1002、HDM1005、DR10624 三款核心品种已推进至Ⅲ期临床。自今年年底开始，公司自研创新药将陆续递交上市申请。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700019705.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0183","BK0188","LU1969619763.USD","BK1161","LU2328871848.SGD","159992","06978","BK0175","BK1574","BK0209","000963","BK0132","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637938648","title":"华东医药(000963.SZ)：赛乐信®和赛捷宁®克罗恩病适应症获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2637938648","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637938648?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:01","pubTimestamp":1779354096,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 华东医药 发布公告，近日，公司全资子公司杭州中美华东制药有限公司收到国家药品监督管理局核准签发的《药品注册证书》及《药品补充申请批准通知书》，由中美华东申报的乌司奴单抗注射液和乌司奴单抗注射液用于克罗恩病的上市许可申请和补充申请获得批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444504.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","BK0175","BK0132","BK4579","BK0188","LU0049112450.USD","LU1046422090.SGD","LU1969619763.USD","LU2328871848.SGD","LX","BK0196","BK4531","IPOS","BK0183","BK4166","LU1235295612.USD","BK0209","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635745502","title":"华东医药（000963）披露将参加深交所2025年度集体业绩说明会，5月14日股价下跌1.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635745502","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635745502?lang=zh_cn&edition=full","pubTime":"2026-05-14 22:10","pubTimestamp":1778767834,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘，华东医药报收于32.8元，较前一交易日下跌1.41%，最新总市值为575.23亿元。近日，华东医药股份有限公司发布《关于参加深圳证券交易所“深研发求精进·积蓄医药成长新动能”2025年度集体业绩说明会的公告》。公告显示，公司将于2026年5月21日15:00-17:00参加由深圳证券交易所组织的2025年度集体业绩说明会，会议地点为深交所8楼上市大厅，采用视频直播与图文转播方式举行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400042801.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2328871848.SGD","BK0183","BK0188","000963","BK0196","BK0132","BK0209","BK0187","BK0175","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635020062","title":"华东医药最新公告：全资子公司注射用HDM2017获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2635020062","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635020062?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:50","pubTimestamp":1778665854,"startTime":"0","endTime":"0","summary":"华东医药(000963.SZ)公告称，公司全资子公司杭州中美华东制药有限公司收到国家药监局核准签发的《药物临床试验批准通知书》，注射用HDM2017联合呋喹替尼治疗晚期结直肠癌的临床试验申请获得批准。该药物为靶向钙黏蛋白17的新型抗体药物偶联物，临床前研究显示良好成药性、安全性和有效性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300033038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","BK0196","BK0175","BK0188","BK0209","LU2328871848.SGD","BK0183","BK0132","000963","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634643425","title":"股市必读：华东医药（000963）5月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2634643425","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634643425?lang=zh_cn&edition=full","pubTime":"2026-05-11 02:03","pubTimestamp":1778436196,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，华东医药报收于33.26元，下跌0.12%，换手率0.38%，成交量6.67万手，成交额2.22亿元。来自公司公告汇总：华东医药将于2026年05月13日参加浙江辖区上市公司投资者网上集体接待日活动，就2025年度及2026年第一季度业绩等事项与投资者交流。关于举办投资者接待日活动的公告华东医药将于2026年05月20日举办投资者接待日活动，时间为当日15:30-17:00，地点为浙江省杭州市拱墅区莫干山路858号公司新大楼3楼远大厅。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100000978.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0183","BK0196","BK0132","LU1969619763.USD","BK0175","000963","LU2328871848.SGD","BK0209","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633433995","title":"华东医药：医美业务经营业绩已完整、准确地体现在公司财务报表中","url":"https://stock-news.laohu8.com/highlight/detail?id=2633433995","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633433995?lang=zh_cn&edition=full","pubTime":"2026-05-08 16:06","pubTimestamp":1778227567,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药05月08日在投资者关系平台上答复投资者关心的问题。让估值起来促进华东品牌效应也会促进下阶段医美产品销售！谢谢华东医药回复：您好！公司始终严格遵守法律法规及企业会计准则，所有年度财务数据均经独立审计并依法披露。医美业务作为公司重要业务板块之一，其经营业绩已完整、准确地体现在公司财务报表中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800026972.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2328871848.SGD","LU1969619763.USD","BK0188","BK0209","BK0175","BK0132","BK0196","BK0183","000963","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633438740","title":"华东医药：HDM3001克罗恩病适应症预计2026年Q2获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2633438740","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633438740?lang=zh_cn&edition=full","pubTime":"2026-05-08 15:51","pubTimestamp":1778226669,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药(000963)05月08日在投资者关系平台上答复投资者关心的问题。投资者提问：公司是否有相关治疗克罗恩病的药物?在这方面后续还有没有新药推出?华东医药回复：您好！公司与荃信生物合作的乌司奴单抗生物类似药HDM3001（QX001S）克罗恩病适应症的注册申请预计将于2026年Q2获批。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800024616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2328871848.SGD","BK0175","BK0187","BK0188","BK0196","BK0183","000963","LU1969619763.USD","BK0209","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633901438","title":"华东医药：HDM1005的MASH适应症已获得中国和美国IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2633901438","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633901438?lang=zh_cn&edition=full","pubTime":"2026-05-08 15:45","pubTimestamp":1778226312,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药(000963)05月08日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在mash领域，除了dr10624，还有哪些布局吗华东医药回复：您好！在MASH治疗领域，公司另一款GLP-1/GIP双靶点长效激动剂HDM1005的MASH适应症已获得中国和美国IND批准。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800023627.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0187","LU1969619763.USD","000963","BK0132","BK0188","LU2328871848.SGD","BK0196","BK0209","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631355374","title":"华东医药：公司自创新转型以来，持续加大研发投入，目前已逐步进入收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2631355374","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631355374?lang=zh_cn&edition=full","pubTime":"2026-04-29 08:48","pubTimestamp":1777423716,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药04月28日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司从19年就开始创新转型，从25年有所起色！公司自创新转型以来，持续加大研发投入，目前已逐步进入收获期。近年来，我们通过自主研发与对外合作双轮驱动，已引入多款具有竞争力的产品，研发效率与质量均在稳步提升。未来，公司将继续聚焦差异化创新，推动公司可持续发展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900027305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0187","000963","BK0175","LU2328871848.SGD","LU1969619763.USD","BK0209","BK0188","BK0132","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630349714","title":"【机构调研记录】东海基金调研理邦仪器、华东医药等4只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2630349714","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630349714?lang=zh_cn&edition=full","pubTime":"2026-04-28 08:04","pubTimestamp":1777334666,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及4月27日披露的机构调研信息，东海基金近期对4家上市公司进行了调研，相关名单如下：1）理邦仪器 调研纪要：2026年一季度公司实现营业收入5.16亿元，同比增长22.82%；归母净利润达1.05亿元，同比增长61.39%。2）华东医药 调研纪要：今年一季度，创新产品对公司收入的贡献持续攀升，当期实现销售及代理服务收入合计8.1亿元，同比增幅达61.8%，占医药工业营业收入比重为20.05%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800026566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0251","BK0114","000963","300206","BK0209","BK0196","BK0146","LU1969619763.USD","BK0175","BK0187","BK0132","BK0183","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630395435","title":"30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=2630395435","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630395435?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:29","pubTimestamp":1777289340,"startTime":"0","endTime":"0","summary":"近日，A股医药板块迎来一季度财报密集披露期，包括阳光诺和、华东医药、重药控股、圣诺生物、我武生物、一品红、丽珠集团、浙江医药、济川药业、科源制药、千红制药等在内的超30家药企集中交出第一季度成绩单。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604273720459429.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604273720459429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK0187","BK0175","300723","BK0196","BK1574","301281","BK0250","000963","688621","BK0188","LU1969619763.USD","06978","600216","BK0183","LU2328871848.SGD","BK0132","002550","BK0209","BK0071","BK0216","000950","688117","BK0239","BK0028","BK0191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1781437956855,"stockEarnings":[{"period":"1week","weight":0.046},{"period":"1month","weight":-0.1065},{"period":"3month","weight":-0.149},{"period":"6month","weight":-0.2828},{"period":"1year","weight":-0.3349},{"period":"ytd","weight":-0.2465}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0497},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0366},{"period":"1year","weight":0.1848},{"period":"ytd","weight":0.0158}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华东医药股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"84304人(较上一季度增加26.48%)","perCapita":"20793股","listingDate":"2000-01-27","address":"浙江省杭州市拱墅区中山北路439号4、7楼","registeredCapital":"175373万元","survey":" 华东医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是商业、制造业、医美业务。","listedPrice":5.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华东医药,000963,华东医药股票,华东医药股票老虎,华东医药股票老虎国际,华东医药行情,华东医药股票行情,华东医药股价,华东医药股市,华东医药股票价格,华东医药股票交易,华东医药股票购买,华东医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}